US EditionSecond phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
- Boston Scientific reported favorable 12-month findings from the ADVANTAGE AF study on April 24, 2025.
- This trial stage assessed the FARAPULSE system and FARAPOINT catheter use in persistent atrial fibrillation patients.
- The prospective trial monitored 255 patients at 29 U.S. Locations after their procedure.
- Findings showed "73.4% freedom from AF, AFL and atrial tachycardia," exceeding the goal.
- The company expects US regulatory approval for persistent AF use of the system.
Insights by Ground AI
Does this summary seem wrong?
22 Articles
22 Articles
All
Left
3
Center
13
Right
Pulsed Field Ablation's Safety Challenged by Evidence of Collateral Damage
(MedPage Today) -- The newer, supposedly safer atrial fibrillation (Afib) ablation systems had safety issues of their own, researchers reported based on multicenter registry data. From several hundred cases starting in March 2024, pulsed field...
·New York, United States
Read Full Article
Boston Scientific reports outcomes from Farapulse and Farapoint trial
Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint systems.The post Boston Scientific reports outcomes from Farapulse and Farapoint trial appeared first on Medical Device Network.
Coverage Details
Total News Sources22
Leaning Left3Leaning Right0Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
L 19%
C 81%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
